XENSE

Executive Summary

XENSE is a San Francisco-based biotech company founded in 2020 that leverages AI-powered digital biomarkers and diagnostic tools for neurological and psychiatric conditions. Its core platform, uTomo, combines next-generation X-ray imaging with advanced AI analysis to enable early detection and monitoring of disorders such as Alzheimer's, Parkinson's, and depression. The company is currently private and seeking investment through crowdfunding platforms, with no disclosed funding rounds, valuation, or revenue. Despite the promising potential of its technology, XENSE has no FDA approvals, commercial products, or publicly announced clinical trials, placing it in a very early-stage development phase. The company operates in the competitive AI diagnostics space, where differentiation and clinical validation are critical for success. Given the lack of concrete milestones or regulatory progress, the investment thesis relies heavily on future execution and validation of its platform.

Upcoming Catalysts (preview)

• Q2 2026Completion of crowdfunding round60% success
• H2 2026Announcement of first clinical trial for uTomo platform40% success
• TBDStrategic partnership with major healthcare provider or pharma company30% success